| Code | CSB-RA024093MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PF-06263507, targeting trophoblast glycoprotein (TPBG), also known as 5T4 or Wnt-activated inhibitory factor 1 (WAIF1). TPBG is a leucine-rich repeat glycoprotein that functions as a Wnt signaling modulator and is highly expressed during embryonic development and trophoblast differentiation. This antigen exhibits restricted expression in normal adult tissues but becomes aberrantly overexpressed in numerous malignancies, including colorectal, ovarian, gastric, and non-small cell lung cancers, where it correlates with poor prognosis, enhanced metastatic potential, and cancer stem cell properties.
PF-06263507 represents a TPBG-targeting antibody-drug conjugate (ADC) that exhibited anti-tumor potential in preclinical studies. This biosimilar antibody serves as a valuable research tool for investigating TPBG biology, tumor microenvironment interactions, and cancer stem cell mechanisms. It enables researchers to explore TPBG as a therapeutic target and biomarker in oncology research, facilitating studies in tumor immunology, metastasis, and targeted therapy development.
There are currently no reviews for this product.